720-777-0123
- Your Visit
-
Research & Innovation
It starts with a Q:
For the latest cutting-edge research, innovative collaborations and remarkable discoveries in child health, read stories from across all our areas of study in Q: Advances and Answers in Pediatric Health.
I believe in providing the most evidence-based and compassionate care possible to my patients and their families. A diagnosis of cancer is one of the worst experiences of a family's life, and making it easier or more manageable to the child and his/her family in some small way is as important to me as providing physical healing. I and my colleagues also strive to treat patients with the most up-to-date in cancer therapies available.
Get to know Amanda Winters, MD
- Aplastic Anemia
- Chemotherapy
- Leukemia (Childhood)
- Myelodysplastic Syndrome
- English
My clinical focus is in the treatment of children with cancer, in particular leukemias and conditions that may lead to leukemias such as inherited bone marrow failure syndromes or myelodysplastic syndromes (MDS).
Undergraduate 2004
University of Southern Mississippi (MS)
Graduate 2011
Tulane University School of Medicine
Medical Education 2011
Tulane University School of Medicine
Internship 2012
Cincinnati Children's Hospital Medical Center Program
Residency 2014
Cincinnati Children's Hospital Medical Center Program
Fellowship 2017
University of Colorado (Children's Hospital Colorado) Program
For Patients:
I perform in-laboratory testing of new drugs that have been developed for acute myeloid leukemia (AML). These drugs are being tested in clinical trials in adults, and may be useful for children with AML as well. I'm also trying to develop more sensitive methods to detect molecular disease when it is not otherwise detectable after therapy, so we can more accurately know how much therapy is needed for individual patients.
I perform in-laboratory testing of new drugs that have been developed for acute myeloid leukemia (AML). These drugs are being tested in clinical trials in adults, and may be useful for children with AML as well. I'm also trying to develop more sensitive methods to detect molecular disease when it is not otherwise detectable after therapy, so we can more accurately know how much therapy is needed for individual patients.
For Referring Providers:
I am investigating targeted therapies for pediatric AML in the pre-clinical setting, including immunotherapies. In addition, I am developing droplet digital PCR assays as an alternative means to measure minimal residual disease in patients with AML.
I am investigating targeted therapies for pediatric AML in the pre-clinical setting, including immunotherapies. In addition, I am developing droplet digital PCR assays as an alternative means to measure minimal residual disease in patients with AML.
Nick Foreman, MD
Hematology/Oncology - Pediatric
Lisa Reaves, MD
Hematology/Oncology - Pediatric
Angie Peltz, PA-C
Physician Assistant
Kathleen (Katie) Dorris, MD
Hematology/Oncology - Pediatric, Pediatrics